Abstract library

9 results for "PKCßII".
#2743 Mimics of Neuroendocrine Neoplasms Identified in a Single Consultation Center between 2009 and 2019
Introduction: Immunohistochemical expression of synaptophysin (SYN), chromogranin (CgA) and cytokeratin are essential for diagnosis of NENs. Non-NENs, however, may occasionally also express NE-markers and cytokeratin and cause diagnostic difficulties.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Atsuko Kasajima
#428 Clinical Manifestations of Patients with Pancreatic ß Cells Hyperplasia
Introduction: Pathologic hyperplasia of pancreatic endocrine cells is uncommon. ß cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia. The manifestations of patients with pancreatic ß cells hyperplasia are variable and their preop. diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Tsann Long Hwang
Authors: Hwang T L, Hsu J T, Shan Y S, ...
#436 Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova
#502 Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice
Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi
Authors: Liu S, Wang Z, Shahi K, Rao D, ...
#619 Diagnostic Accuracy of F-18-DOPA PET or PET/CT in Neuroendocrine Tumors: A Meta-Analysis
Introduction: A specific feature of NETs is amine precursor uptake and decarboxylation; this is the rationale for using PET with F-18-DOPA, a cathecholamine precursor, in diagnosis of NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Barbara Muoio
Authors: Muoio B, Treglia G, Rufini V, ...
#1078 Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET
Introduction: ACTH production from a midgut mesentery NET is extremely rare (1). A 62y old woman presented with hypokalaemia (2mmol/L) and hyperpigmentation, 11y after surgery of a pT3N1Mx non-functional G1 NET with SRS positive, non-resectable but stable, residual mass encasing mesenteric vessels. Serum cortisol (3261 nmol/L), ACTH (796 ng/L), CgA (530 pmol/L) and urine total cortisol metabolites (33920 µg/24h) including 14 sub-products indicated change of biological behaviour into a functioning NET. Pituitary or pulmonary sources were excluded
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr., Ass Prof. Martin O. Weickert
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#1372 The Role of Interval CT Scanning in Patients Undergoing Palliative Chemotherapy for Metastatic Neuroendocrine Tumours (NETs)
Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Rowan Miller
Authors: Miller R, Childs A, Gillmore R, Mayer A, ...
#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide
Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel